Is The Allergen Really Needed in Allergy Immunotherapy?

被引：0
作者：
Kündig T.M. [1 ]
Klimek L. [2 ]
Schendzielorz P. [2 ]
Renner W.A. [3 ]
Senti G. [4 ]
Bachmann M.F. [1 ,5 ]
机构：
[1] Dermatology Department, Zurich University Hospital, Gloriastr. 31, Zurich
[2] Zentrum für Rhinologie und Allergologie, Wiesbaden
[3] AREBA Biotech AG, Kilchberg
[4] Center for Clinical Trials, Zürich
[5] National Center for Cancer Care and Research, Hamad Medical Corporation, Doha
来源：
Current Treatment Options in Allergy | 2015年 / 2卷 / 1期
关键词：
Allergic rhinitis; Allergy; CpG motifs; Immunotherapy; Vaccine; Virus-like particles;
D O I：
10.1007/s40521-014-0038-5
中图分类号：
学科分类号：
摘要：
Immunotherapy for type I allergies is well established and is regarded to be the most efficient treatment option besides allergen avoidance. As of today, different forms of allergen preparations are used in this regard, as well as different routes of application. Virus-like particles (VLPs) represent a potent vaccine platform with proven immunogenicity and clinical efficacy. The addition of toll-like receptor ligands and/or depot-forming adjuvants further enhances activation of innate as well as adaptive immune responses. CpG motifs represent intensively investigated and potent direct stimulators of plasmacytoid dendritic cells and B cells, while T cell responses are enhanced indirectly through increased antigen presentation and cytokine release. This article will focus on the function of VLPs loaded with DNA rich in nonmethylated CG motifs (CpGs) and the clinical experience gained in the treatment of allergic rhinitis, demonstrating clinical efficacy also if administered without allergens. Several published studies have demonstrated a beneficial impact on allergic symptoms by treatment with CpG-loaded VLPs. Subcutaneous injection of VLPs loaded with CpGs was tested with or without the adjuvant alum in the presence or absence of an allergen. The results encourage further investigation of VLPs and CpG motifs in immunotherapy, either as a stand-alone product or as adjuvants for allergen-specific immunotherapy. © 2014, The Author(s).
引用
收藏
页码：72 / 82
页数：10
相关论文
共 82 条
  • [21] Patel D., Et al., Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study, J Allergy Clin Immunol, 131, 103-109, pp. e101-e107, (2013)
  • [22] Senti G., Et al., Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial, Proc Natl Acad Sci U S A, 105, pp. 17908-17912, (2008)
  • [23] Senti G., Johansen P., Kundig T.M., Intralymphatic immunotherapy: from the rationale to human applications, Curr Top Microbiol Immunol, 352, pp. 71-84, (2011)
  • [24] Kundig T.M., Johansen P., Bachmann M.F., Cardell L.O., Senti G., Intralymphatic immunotherapy: time interval between injections is essential, J Allergy Clin Immunol, 133, pp. 930-931, (2014)
  • [25] Senti G., Et al., Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections, J Allergy Clin Immunol, 129, pp. 1290-1296, (2012)
  • [26] Hylander T., Latif L., Petersson-Westin U., Cardell L.O., Intralymphatic allergen-specific immunotherapy: an effective and safe alternative treatment route for pollen-induced allergic rhinitis, J Allergy Clin Immunol, 131, pp. 412-420, (2013)
  • [27] Mondoulet L., Et al., Epicutaneous immunotherapy (EPIT) blocks the allergic esophago-gastro-enteropathy induced by sustained oral exposure to peanuts in sensitized mice, PLoS One, 7, (2012)
  • [28] Mondoulet L., Et al., Epicutaneous immunotherapy on intact skin using a new delivery system in a murine model of allergy, Clin Exp Allergy, 40, pp. 659-667, (2010)
  • [29] Mondoulet L., Et al., Epicutaneous immunotherapy compared with sublingual immunotherapy in mice sensitized to pollen (Phleum pratense), ISRN Allergy, 2012, (2012)
  • [30] Mondoulet L., Et al., Intact skin and not stripped skin is crucial for the safety and efficacy of peanut epicutaneous immunotherapy (EPIT) in mice, Clin Transl Allergy, 2, (2012)
123456789